Cryosite Ltd (CTE) - Total Assets
Based on the latest financial reports, Cryosite Ltd (CTE) holds total assets worth AU$26.55 Million AUD (≈ $18.78 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Cryosite Ltd (CTE) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Cryosite Ltd - Total Assets Trend (2001–2025)
This chart illustrates how Cryosite Ltd's total assets have evolved over time, based on quarterly financial data. See CTE net asset value for net asset value and shareholders' equity analysis.
Cryosite Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Cryosite Ltd's total assets of AU$26.55 Million consist of 45.6% current assets and 54.4% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 26.0% |
| Accounts Receivable | AU$2.29 Million | 11.7% |
| Inventory | AU$43.00K | 0.2% |
| Property, Plant & Equipment | AU$1.42 Million | 7.3% |
| Intangible Assets | AU$2.00 Million | 10.3% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Cryosite Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CTE market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cryosite Ltd's current assets represent 45.6% of total assets in 2025, a decrease from 70.4% in 2001.
- Cash Position: Cash and equivalents constituted 26.0% of total assets in 2025, down from 68.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 11.7% of total assets.
Cryosite Ltd Competitors by Total Assets
Key competitors of Cryosite Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
Cryosite Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.49 | 1.78 | 1.62 |
| Quick Ratio | 0.48 | 1.77 | 1.61 |
| Cash Ratio | 0.00 | 0.00 | 1.27 |
| Working Capital | AU$-5.73 Million | AU$3.40 Million | AU$2.11 Million |
Cryosite Ltd - Advanced Valuation Insights
This section examines the relationship between Cryosite Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 13.52 |
| Latest Market Cap to Assets Ratio | 2.13 |
| Asset Growth Rate (YoY) | -1.3% |
| Total Assets | AU$19.46 Million |
| Market Capitalization | $41.44 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Cryosite Ltd's assets at a significant premium (2.13x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Cryosite Ltd's assets decreased by 1.3% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Cryosite Ltd (2001–2025)
The table below shows the annual total assets of Cryosite Ltd from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$19.46 Million ≈ $13.77 Million |
-1.26% |
| 2024-06-30 | AU$19.71 Million ≈ $13.95 Million |
-12.96% |
| 2023-06-30 | AU$22.65 Million ≈ $16.02 Million |
+5.32% |
| 2022-06-30 | AU$21.50 Million ≈ $15.21 Million |
-2.23% |
| 2021-06-30 | AU$21.99 Million ≈ $15.56 Million |
-6.42% |
| 2020-06-30 | AU$23.50 Million ≈ $16.63 Million |
+1.42% |
| 2019-06-30 | AU$23.17 Million ≈ $16.40 Million |
+199.24% |
| 2018-06-30 | AU$7.74 Million ≈ $5.48 Million |
-21.20% |
| 2017-06-30 | AU$9.83 Million ≈ $6.95 Million |
+1.76% |
| 2016-06-30 | AU$9.66 Million ≈ $6.83 Million |
+5.86% |
| 2015-06-30 | AU$9.12 Million ≈ $6.45 Million |
-18.49% |
| 2014-06-30 | AU$11.19 Million ≈ $7.92 Million |
-1.49% |
| 2013-06-30 | AU$11.36 Million ≈ $8.04 Million |
+16.29% |
| 2012-06-30 | AU$9.77 Million ≈ $6.91 Million |
+13.28% |
| 2011-06-30 | AU$8.63 Million ≈ $6.10 Million |
+12.27% |
| 2010-06-30 | AU$7.68 Million ≈ $5.44 Million |
+4.46% |
| 2009-06-30 | AU$7.35 Million ≈ $5.20 Million |
+1.46% |
| 2008-06-30 | AU$7.25 Million ≈ $5.13 Million |
+13.30% |
| 2007-06-30 | AU$6.40 Million ≈ $4.53 Million |
+25.10% |
| 2006-06-30 | AU$5.11 Million ≈ $3.62 Million |
+9.71% |
| 2005-06-30 | AU$4.66 Million ≈ $3.30 Million |
+5.87% |
| 2004-06-30 | AU$4.40 Million ≈ $3.12 Million |
+24.92% |
| 2003-06-30 | AU$3.52 Million ≈ $2.49 Million |
-19.14% |
| 2002-06-30 | AU$4.36 Million ≈ $3.08 Million |
+7.68% |
| 2001-06-30 | AU$4.05 Million ≈ $2.86 Million |
-- |
About Cryosite Ltd
Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more